Quantcast

Latest Boehringer Ingelheim Corporation Stories

2014-04-30 12:30:17

- First results of the pivotal Phase 3 INPULSIS(TM) trials investigating the efficacy and safety of nintedanib, an investigational compound, in the treatment of idiopathic pulmonary fibrosis (IPF) RIDGEFIELD, Conn., April 30, 2014 /PRNewswire/ -- Boehringer Ingelheim announced today that the first results from two highly anticipated Phase 3 trials in idiopathic pulmonary fibrosis (IPF) and in chronic obstructive pulmonary disease (COPD) will be presented at the 2014 American...

2014-04-17 08:28:00

RIDGEFIELD, Conn., April 17, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation to volasertib for acute myeloid leukemia (AML). Volasertib is currently being evaluated in a Phase III clinical trial for the treatment of patients aged 65 or older, with previously untreated AML, who are ineligible for intensive remission induction therapy....

2014-04-14 12:34:34

RIDGEFIELD, Conn. and INDIANAPOLIS, April 14, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (Lilly; NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) accepted the filing of the New Drug Application (NDA) for the investigational combination tablet of empagliflozin and linagliptin for the treatment of adults with type 2 diabetes (T2D). If granted approval by the FDA, this combination will bring together, for the first time into...

2014-04-08 12:31:49

Three pivotal trials showed PRADAXA as non-inferior to warfarin in reduction of DVT and PE recurrence; fourth pivotal trial showed PRADAXA reduced risk of recurrence by 92 percent compared to placebo RIDGEFIELD, Conn., April 8, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa(®) (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in...

2014-04-07 08:31:34

Three pivotal trials showed PRADAXA as non-inferior to warfarin in reduction of DVT and PE recurrence; fourth pivotal trial showed PRADAXA reduced risk of recurrence by 92 percent compared to placebo RIDGEFIELD, Conn., April 7, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa(®) (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in...

2014-03-28 08:27:23

Cardiologists also believe their patients' top concern is the fear of experiencing a clot that leads to a stroke; real-world challenges may influence treatment decisions RIDGEFIELD, Conn., March 28, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced results from a new survey of cardiologists to understand their perceptions about anticoagulation, stroke risk reduction and goals for non-valvular atrial fibrillation (NVAF) therapy when prescribing warfarin or...

2014-03-24 08:28:21

Presentations to include research around antidote for dabigatran, a post-hoc analysis of data from the RE-LY® trial and data from the GLORIA(TM)-AF registry RIDGEFIELD, Conn., March 24, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that data from three company-sponsored PRADAXA studies will be presented at the American College of Cardiology 63(rd) Annual Scientific Session (ACC.14) in Washington, D.C., March 29 to 31, 2014. An oral presentation will...

2014-03-21 08:24:55

Positive opinion is based on data from one of the largest clinical registration programs in its class, involving more than 13,000 adults with type 2 diabetes RIDGEFIELD, Conn. and INDIANAPOLIS, March 21, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, recommending approval of empagliflozin, an...

2014-03-06 08:30:17

Additional drug-drug interaction data for faldaprevir combined with commonly prescribed HIV medications also presented at CROI 2014 INGELHEIM, Germany and RIDGEFIELD, Conn., March 6, 2014 /PRNewswire/ -- Today Boehringer Ingelheim announced results from STARTVerso(®)4 in patients with HCV/HIV co-infection. Hepatitis C viral cure 12 weeks after the conclusion of treatment (SVR12) was achieved by 72% of all patients in the trial. Patients were enrolled in either 120mg or 240mg...

2014-03-05 12:26:22

Boehringer Ingelheim and Lilly are committed to working with the FDA RIDGEFIELD, Conn. and INDIANAPOLIS, March 5, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (Lilly; NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the New Drug Application (NDA) of the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin. The complete response letter...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'